LNTH Earnings Date: Nov 5, 2026 (Estimated) — Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is LNTH's next earnings date?
Lantheus Holdings, Inc. (LNTH) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.26 on revenue of $360.8M.
How did LNTH do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Lantheus Holdings, Inc. posted EPS of $1.55 versus the $1.30 estimate, a beat of 23.0%. Revenue was $388.2M against a $363.2M estimate. The stock's 1-day post-earnings move was -0.4%.
How much does LNTH stock move after earnings?
LNTH beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.4% (up or down) in the day after earnings.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.30 | 1.55 | +23.02% | $388.2M | ✅ Beat | -0.42% | -0.76% | -0.51% |
| 2026-05-07 | Q1 2026 | 1.19 | 1.46 | +22.69% | $377.3M | ✅ Beat | +5.63% | +11.97% | +17.21% |
| 2026-02-26 | Q4 2025 | 1.08 | 1.67 | +54.63% | $406.8M | ✅ Beat | -0.38% | +2.80% | +0.85% |
| 2025-11-06 | Q3 2025 | 1.18 | 1.27 | +7.63% | $384.0M | ✅ Beat | -6.19% | -4.77% | +10.61% |
| 2025-08-06 | Q2 2025 | 1.58 | 1.57 | -0.63% | $378.0M | ❌ Miss | -28.58% | -25.79% | -25.90% |
| 2025-02-26 | Q4 2024 | 1.54 | 1.59 | +3.25% | $391.1M | ✅ Beat | +16.49% | +22.64% | +22.96% |
| 2024-11-06 | Q3 2024 | 1.56 | 1.70 | +8.97% | $378.7M | ✅ Beat | -20.69% | -25.93% | -22.29% |
| 2024-07-31 | Q2 2024 | 1.83 | 1.80 | -1.64% | $394.1M | ❌ Miss | -4.50% | -10.59% | -0.05% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.07B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 35.4% | $376.9M | +0.6% | $388.1M | $366.9M | $374.5M | $376.7M |
| Oncology | 22.6% | $240.4M | — | — | — | — | — |
| PYLARIFY | 22.6% | $240.4M | -4.1% | $266.0M | $257.7M | $250.6M | $240.6M |
| Cardiology | 8.3% | $88.3M | — | — | — | — | — |
| DEFINITY | 8.3% | $88.3M | +5.2% | $86.2M | $79.2M | $83.9M | $81.8M |
| Strategic Partnerships And Other | 1.9% | $19.9M | +71.9% | $7.7M | $10.7M | $11.6M | $13.7M |
| License and Royalty Revenues | 1.1% | $11.2M | +221.5% | $3.0M | $5.8M | $3.5M | $7.3M |
By region
Q2 FY26 · $388.2M total
| Segment | Share | Revenue | YoY | Q2 FY26 |
|---|---|---|---|---|
| UNITED STATES | 94.9% | $368.3M | — | $368.3M |
| Non-US | 5.1% | $19.9M | — | $19.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.